更新一下，我想也算是好消息吧，虽然只是ACT自己网站上的消息：http://www.advancedcell.com/news ... milestone/index.asp
摘要：
* Investigators for the Company’s Phase I/II clinical trials for Stargardt’s macular dystrophy (SMD) and dry age-related macular degeneration (dry AMD) have observed evidence of engraftment of the transplanted human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells and visual acuity gain in patients treated over the 18 months since the trials were first initiated.
经查，在针对干性黄斑萎缩和斯特格病变的临床试验I/II期中，有证据表明移植的人体胚胎干细胞已定植，且自植入之后18个月内，促生试验病患的RPE细胞并促其获得视力（此处没有说明，但我记得柳叶刀里面提到应该是部分视力，表现为读取字数的增多）。
* The Company believes this observation of engraftment and persistence is clinically important because engraftment of cells in the proper area, and recapitulation of normal RPE cell layer structure is important to the ultimate efficacy of the RPE cells in the treatments.
公司认为这定植和留存的观察结果具有临床重大意义，因为这表明植入的区域是正确的，并且在治疗中重演正常RPE细胞表层结构对最终RPE细胞的有效性是相当重要的。
* Additionally, investigators have not observed any issues of safety relating to the transplanted human embryonic stem cell (hESC)-derived RPE cells in any of the 18 patients treated. The company believes this warrants early (though cautious) optimism as the company looks forward to initiating the second half of the three trials.
此外，在对已经进行的18例病患植入中，调查没有发现相关的安全性问题。尽管仍然谨慎，但公司相信在即将进行另半临床试验中，这是一个乐观的信号。
后面他们波斯说的话就不贴了，怕带有太多的主观性。 |
